Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer

BACKGROUND: We have recently described the correlation between quantitative measures of HER2 expression or HER2 homodimers by the HERmark assay and objective response (RR), time-to progression (TTP), and overall survival (OS) in an expanded access cohort of trastuzumab-treated HER2-positive patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, Masakazu, Sperinde, Jeff, Huang, Weidong, Saji, Shigehira, Winslow, John, Jin, Xueguang, Tan, Yuping, Ohno, Shinji, Nakamura, Seigo, Iwata, Hiroji, Masuda, Norikazu, Aogi, Kenjiro, Morita, Satoshi, Petropoulos, Christos, Bates, Michael
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837013/
https://www.ncbi.nlm.nih.gov/pubmed/20178580
http://dx.doi.org/10.1186/1471-2407-10-56

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837013/
https://www.ncbi.nlm.nih.gov/pubmed/20178580
http://dx.doi.org/10.1186/1471-2407-10-56

Ejemplares similares